We have developed a sensitive bioassay for transforming genes based on the tumorigenicity of cotransfected NIH3T3 cells in nude mice. The assay differs substantially from the NIH3T3 focus assay. Using it, we have detected the transfer of three transforming genes from the DNA of MCF-7, a human mammary carcinoma cell line. One of these is N-ras, which is amplified in MCF-7 DNA. The other two, which we have called mcf2 and mcf3, do not appear to be related to known oncogenes. We cannot detect their transfer by using the NIH3T3 focus assay. We do not yet know whether either mcf2 or mcf3 is associated with genetic abnormalities in MCF -7 cells.
The transfer of genomic DNA into NIH3T3 cells has led to the discovery that genes present in some tumor cells are capable of inducing foci of morphologically transformed NIH3T3 cells (24, 27, 31, 33, 40) . Most of the transforming genes which have been detected this way have now been identified as members of the ras gene family, either H-, K-, or N-ras (8, 17, 29, 33, 36, 43) . The transforming ras genes detected by the NIH3T3 focus assay have structural gene mutations that account for their transforming activity (34, 48, 50, 51, 55) . Since the great majority of tumor DNAs tested fail to induce transformed foci (24, 31, 33) , we have speculated that the focus assay has a bias for ras genes containing structural mutations. Therefore, we have begun a series of experiments to explore alternative assays for transforming genes present in NIH3T3 cells after DNA transfer. We describe here some preliminary results with an assay system that detects new oncogenes. The system is a modification of the one described by Blair and co-workers (2) . Like theirs, our assay also relies on the ability of transformed NIH3T3 cells to form tumors in nude mice, but incorporates methods of cotransfection (54) to heighten sensitivity. Using this assay, we have transferred three human transforming genes from the DNA of MCF-7, a human breast carcinoma cell line. One of these is N-ras. The other two appear to be unrelated to previously known transforming genes. The Nras gene is amplified in MCF-7 cells but does not appear to contain structural mutations. We have not yet established whether the other two genes, which we have called mcf2 and mcf3, are associated with any genetic abnormality in MCF-
MATERIALS AND METHODS
Preparation and source of DNA. High-molecular-weight DNA from various cell lines was prepared as described previously (31) . MCF-7 was from the Human Tumor Cell Line Bank of the Sloan Kettering Institute, Rye, N.Y. (44) . Preparation of DNA from solid tumors was done as follows. Tumors (1 to 2 g offrozen tissue) were finely ground by using a pestle in a mortar containing liquid N2. The resulting powder was added to 40 ml of 400 mM NaCl-10 mM EDTA-20 mM Tris-hydrochloride (pH 7.5)-0.5% sodium dodecyl sulfate prewarmed at 68°C and incubated at this temperature * Corresponding author.
for 20 min. An additional incubation at 37°C in the presence of proteinase K at the final concentration of 200 ,ug/ml was carried out with very slow agitation for 24 to 48 h. Phenol extraction and subsequent steps were as described previously (31) . Plasmid and phage DNAs were prepared by published methods (21, 49) . Many plasmids that were used in this study were generously provided by the following scientists: pKOneo, D. Hanahan; psrc-11, G. Cooper; pBR-Y73, N. Kitamura; pAB-sub3, S. Goff; pGA-FeSV, C. Sherr; pRCII-1B, H. Hanafusa; pBR-UR2, H. Hanafusa; pAEPvuII, M. Bishop; pHB-11, E. Scolnick; pKBE-2, E. Scolnick; pm-1, D. Blair; pMCV38, M. Bishop; pVM-2, M. Bishop; pFBJ-2, I. Verma; pSSV-11, S. Aaronson; pREV-T3, H. Temin; pvski-1, E. Stavnezer; pMT-2.5, H. Varmus; pSM-FeSV, C. Sherr; and blur 8, C. Schmid. Phage X myc4.1.1 was from M. Cole.
DNA transfections and nude mice assay. All DNA transfers used a modified calcium phosphate precipitation method (15, 54) with NIH3T3 cells as recipients (19, 31) . Focus assays were performed as previously described (31) . For the nude mouse experiments, 30 ,ug of cellular DNA plus 300 ng of pKOneo plasmid, constructed by D. Hanahan (unpublished data), were added as a calcium phosphate precipitate (volume, 1 ml) to each 100-mm culture dish containing 5 x 105 cells in 10 ml of Dulbecco medium and 10% calf serum (D10). After incubation for 8 h, the precipitate was removed and replaced by 10 ml of fresh D10. After an additional 6 h, the cells in each plate were trypsinized and seeded into four 100-mm dishes containing D10 plus 0.4 g of the antibiotic G418 (GIBCO Laboratories) per liter (as calculated for 100% active antibiotic). This time schedule is critical, since the antibiotic efficiently selects cells expressing the resistance marker only when seeding is done at low cell density. Refeeding of the cultures was done at intervals of 3 days, using the same medium. The plates, each containing about 300 colonies, reached confluency after 16 to 18 days. At this time, the four plates of cells were trypsinized, pooled, centrifuged at 700 rpm for 5 min, and resuspended in 0.25 ml of D10. Approximately 107 cells were injected subcutaneously over the right shoulders of athymic, 4-to 8-week-old male or female Nu-Nu mice of Rex-Trembler origin which had been back-crossed to Swiss three times. One deviation from this protocol is described in the footnote to (14, 31) . As a negative control, one set of mice is inoculated with cells exposed to genomic DNA from NIH3T3 cells. Mice are maintained for up to 3 months.
Our first experiments with the tumorigenicity assay were performed with DNA from a human breast carcinoma cell line, MCF-7. Lane et al. had previously reported MCF-7 DNA to be positive in the NIH3T3 focus assay (25) . However, we had consistently failed to observe any induced foci when using this DNA as donor. Nevertheless, we did obtain positive results using MCF-7 DNA in the nude mouse assay (Tables 1 and 2 ). In two experiments, three independent tumors were obtained. There was a low tumor incidence in the negative control group (see tables) as well as in mice injected with NIH3T3 cells exposed to human placental DNA (data not shown). There is, therefore, a background of tumor induction when testing normal DNA, a point to which we will return later. With MCF-7 DNA, as with many other tumor DNAs we have since examined, tumor incidence was higher than with control DNAs, but this may not be statistically significant. We therefore do not assume that the positive results with MCF-7 DNA reflect a genetic abnormality in MCF-7 cells. The assay is, however, clearly responsive to high copies of strongly transforming genes since tumor incidence is markedly increased with the positive control groups, consisting of nude mice injected with NIH3T3 exposed to DNA from al-1.
We call tumors resulting from cells exposed to MCF-7 DNA primary tumors MCF-7-1, MCF-7-2, and MCF-7-3. DNAs prepared from the primary tumors were used again in the tumorigenicity assay to obtain secondary tumors. The lineages of the relevant tumors are given in Table 3 . In each case, DNA from the primary tumor was significantly more (14, 31) . MCF-7 is a human breast cancer cell line (44) . Tumors designated MCF-7-la through MCF-7-lg all derived from the same initial transformed NIH3T3 cell since they display identical Southern blot patterns when probed from human repeat sequences (data not shown). This is consistent with their origin from a single pool of transformants. These tumors are referred to collectively as MCF-7-1. In subsequent experiments, we avoided this problem by injecting each mouse with an independent pool of transformed cells. See text for more details. active at inducing tumorigenic NIH3T3 than the original MCF-7 DNA itself (see, for example, Table 2 ). This probably results from the amplification of the transforming gene in primary transformants (see below). Despite their higher activity in the nude mouse assay, DNAs from primary tumors still cannot induce foci of morphologically altered NIH3T3 cells. This reflects, we think, an intrinsic difference between the present assay and the focus assay.
DNAs from primary and secondary tumors were prepared and analyzed by Southern blotting for the presence of human repetitive sequences (Fig. 1) . This powerful method allows the comparison of our putative transforming genes before their actual isolation (27, 31) . All secondary tumors derived from the same primary tumor DNA contained a common set of human repetitive sequences. However, these sets differed among secondary tumors derived from different primary tumor DNAs. From this observation we conclude that the nude mouse assay appears to detect three different transforming genes in the DNA of MCF-7 which we called mcfl, mcf2, and mcf3. This conclusion was confirmed by subsequent experiments, described below.
Relation of mcf genes to the known ras genes. DNAs from the three primary tumors were analyzed for the presence of the three human ras genes, N-, H-, and K-ras, by Southern analysis. Neither MCF-7-2 nor MCF-7-3 contained these genes. Later studies showed that indeed the mcf2 and mcf3 genes are not even weakly related to members of the ras gene family (see below).
DNA from MCF-7-1, however, contained 30 to 100 copies of the human N-ras gene (Fig. 2) . Moreover, all secondary tumors derived from MCF-7-1 DNA contained a similar number of copies of the human N-ras gene. Therefore, mcfl was N-ras. Although EcoRI fragments with homology to Nras are seen in the MCF-7-1 secondary DNAs, they are not the expected size. We cloned the N-ras gene from one of these DNAs (MCF-7-1-1) and analyzed its structure. It contained the 9.2-kbp fragment, which corresponds to the intact 5' end of the N-ras gene (50) , but had undergone rearrangement in sequences which flanked the 3' end of the gene. We next examined the possibility that the N-ras gene of MCF-7 was itself rearranged. We performed Southern blot analysis of MCF-7 DNA with an N-ras probe and observed that this gene was not rearranged, at least within the 16.3-kbp region containing a functional N-ras gene. This was definitely established by the cloning of the N-ras region from MCF-7 DNA. We conclude that rearrangement of the (14, 30) .
These same studies, however, did indicate that the N-ras gene of MCF-7 is present at several times the copy number found in normal human diploid cells (Fig. 2) translated total human DNA and performing a second autoradiographic exposure. These studies indicated that Nras was present in MCF-7 cells at 5 to 10 times the levels seen in cultured diploid human fibroblasts and human placental cells. Induction of tumors with ras genes encoding normal proteins. We were surprised to find that DNA from MCF-7-1 could not induce morphologically altered foci in NIH3T3 cells. When the N-ras gene was cloned from a tumor induced by MCF-7-1 DNA, it too was unable to induce foci in NIH3T3 cells. Since the focus assay is sensitive to activated ras genes containing structural mutations, we tentatively concluded that the N-ras gene of MCF-7 encodes a normal protein product and, further, that the tumorigenicity assay, unlike the focus assay, is sensitive to cellular genes with the potential to induce tumorigenicity by increased expression of unaltered protein products.
We directly tested this hypothesis by assaying an activated H-ras gene cloned from T24 bladder carcinoma cells (51), a wild-type H-ras gene cloned from human placental cells (51) , an activated N-ras gene cloned from SK-N-SH cells (50) , and a wild-type N-ras gene cloned from human placental cells (50) ( Table 3) . The results are summarized in Table  4 . The structurally mutated, transforming H-ras and N-ras genes efficiently induced tumors. The H-ras and N-ras genes cloned from human placental DNA were much less active but did nevertheless efficiently induce tumors in nude mice. We attribute this to the presence of multiple copies of these genes in NIH3T3 cells after DNA transfer, a hypothesis consistent with the work of others (5), who have shown that cells expressing high levels of the human H-ras gene product are tumorigenic.
It was still possible that the N-ras gene of MCF-7 contained mutations which made it more active in the tumorige- Preliminary characterization of the mcf2 and mcf3 genes. We have cloned portions of the two other genes detected by our assay of MCF-7 DNA. We used human repetitive sequences to isolate these genes from A phage libraries we constructed using DNA from secondary tumors MCF-7-2-2 and MCF-7-3-4. In retrospect, this isolation was greatly facilitated by the high copy number of these genes present in induced mouse tumors (see Fig. 5 ). From overlapping A phage inserts we determined preliminary EcoRI maps of these genes (Fig. 3) . We also determined the presence of mouse or human repeat sequences on these genes ( Fig. 3 and  4) . None of our clones have shown strong hybridization to total nick-translated mouse DNA (Fig. 4D ), but we observed weak hybridization between some fragments and mouse DNA upon long autoradiographic exposures (Fig. 4C) . We attribute this to weak homology between human and mouse sequences since sequences which were cloned directly from the human cell line MCF-7 also showed this weak hybridization (Fig. 4, lane h ). We present this data to facilitate the subsequent unambiguous identification of new oncogenes as they become isolated by others. However, we caution that the human DNA which we have isolated may contain rearrangements. Since none of our phage clones is biologically active in the nude mouse assay, these genes may be too large to clone in a biologically active form as a A phage insert, and we are currently isolating cosmid clones.
By blotting our cloned DNAs with total human or mouse DNA, we identified relatively repeat-free restriction endonuclease fragments useful for Southern hybridization to genomic DNAs. We then were able to examine the copy number of these genes in our various transformants, in MCF-7 cells themselves, and in transformed NIH3T3 cells obtained from G. Cooper which he obtained by using MCF-7 DNA in a focus assay (Fig. 5) . Evidently, the mcf2 and mcf3 genes are not related to each other. They are present in high copy numbers in the primary tumors MCF-7-2 and MCF-7-3, respectively, and in the respective secondary tumors derived from them. However, neither gene appears to be amplified in MCF-7 DNA itself. Significantly, neither gene appears to be related to the gene that Lane et al. (25) reported to transfer from MCF-7 DNA to NIH3T3 cells using an NIH3T3 focus assay (Fig. 5, lanes h and i) .
We finally used our cloned DNA as probes to search for homology to known oncogenes. This was done by lowstringency blot hybridization to complete or nearly complete oncogene clones. For probes, we nick translated a total of 39.7 and 28.3 kbp from mcf2 and mcf3, respectively. No homology was seen to the clones of oncogenes shown in Table 5 (blot data not shown). Since this survey includes most of the known cellular oncogenes, we conclude that mcf2 and mcf3 are previously uncharacterized transforming genes. This conclusion must be taken with caution, since we do not know if the cloned portions of the mcf genes include coding sequences. ; . -. . n." nude mice directly after exposure to tumor DNA. Our method differs from theirs in the use of cotransfection. The decision to utilize cotransfection, with selection for G418 resistance, was based on the following considerations. First, selection for a biochemical marker preselects for cells competent in the uptake of DNA (54) (25) . Neither the mcJ2 nor the mcf3 gene appears to be related to the gene reported by those workers. A more definitive conclusion, however, must await the identification of mc]2 and mcJ3 coding regions. We do not know if the mcJ2 and mcJ3 genes of MCF-7 cells have genetic abnormalities. On the one hand, it would not be particularly surprising to find multiple weakly transforming genetic lesions in MCF-7 cells or, for that matter, most tumorigenic cells. On the other hand, neither would it be surprising if either or both mcf2 and mcJ3 are indeed normal genes which can induce tumorigenicity by overexpression after gene transfer into NIH3T3 cells. To answer these questions, it will be necessary to clone these genes in a biologically active form both from MCF-7 and from normal human DNA to compare their transforming activities. In summary, we have described a tumorigenicity assay for transforming genes which differs considerably from the NIH3T3 focus assay. We do not fully understand the basis of this difference, nor do we know if the genes we detect with the assay will usually reflect genetic abnormalities in the DNA being tested. Indeed, our results strongly suggest that, with some frequency, normal genes with transforming potential will sometimes be detected. Nevertheless, we appear to have uncovered a previously unknown genetic abnormality in MCF-7 cells and have probably discovered two previously unknown human oncogenes.
